Literature DB >> 17606790

Zebra lines of pamidronate therapy in children.

M Al Muderis1, T Azzopardi, P Cundy.   

Abstract

BACKGROUND: Pamidronate therapy is increasingly used in children for the treatment of low bone mineral density and increased bone fragility resulting from a spectrum of conditions. The aim of the present study was to determine and describe the radiographic features associated with cyclical bisphosphonate therapy in the growing skeleton.
METHODS: A retrospective review of the radiographs of thirty-five children who had been managed with cyclical pamidronate was carried out. The physeal growth rates were estimated by measuring the band intervals on radiographs and the corresponding time intervals between the administered doses of pamidronate.
RESULTS: Metaphyseal bands, which we call zebra lines, were observed with band intervals that were dependent on the age of the patient, the rate of growth, and the dosing regimen. Epiphyseal and apophyseal bands were also observed in some patients. A distinction was made between Harris growth arrest lines and zebra lines. There was no evidence to suggest a deceleration in bone growth in children managed with pamidronate.
CONCLUSIONS: The term zebra lines is proposed as a descriptive term for the characteristic pattern of metaphyseal banding seen on the radiographs of children receiving cyclical bisphosphonate therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17606790     DOI: 10.2106/JBJS.F.00726

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  16 in total

Review 1.  Founders lecture 2007: Metabolic bone disease: what has changed in 30 years?

Authors:  Murali Sundaram
Journal:  Skeletal Radiol       Date:  2009-03-05       Impact factor: 2.199

2.  Characteristic Bands Manifesting as Zebra Lines on Radiographs in Osteogenesis Imperfecta.

Authors:  Mariko Ishizuka; Shoji Tsuji; Masato Hirabayashi; Kazunari Kaneko
Journal:  Indian J Pediatr       Date:  2017-02-24       Impact factor: 1.967

3.  Approach to the child with fractures.

Authors:  Alison M Boyce; Rachel I Gafni
Journal:  J Clin Endocrinol Metab       Date:  2011-07       Impact factor: 5.958

4.  Zebra lines in osteogenesis imperfecta on bisphosphonate therapy.

Authors:  Suja P Sukumar; Karthik Balachandran; Jaya Prakash Sahoo; Sadishkumar Kamalanathan
Journal:  BMJ Case Rep       Date:  2013-02-25

5.  Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome.

Authors:  Alessandro Corsi; Ernesto Ippolito; Pamela G Robey; Mara Riminucci; Alan Boyde
Journal:  Skeletal Radiol       Date:  2017-06-28       Impact factor: 2.199

6.  Pamidronate treatment stimulates the onset of recovery phase reducing fracture rate and skeletal deformities in patients with idiopathic juvenile osteoporosis: comparison with untreated patients.

Authors:  Giampiero I Baroncelli; Francesco Vierucci; Silvano Bertelloni; Paola Erba; Elisa Zampollo; Maria Rita Giuca
Journal:  J Bone Miner Metab       Date:  2013-04-03       Impact factor: 2.626

7.  Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report.

Authors:  V J V Vigorita; J S Silver; E O E Eisemon
Journal:  Skeletal Radiol       Date:  2012-04-18       Impact factor: 2.199

8.  Metaphyseal bands in osteogenesis imperfecta.

Authors:  Ss Suresh; John K Thomas
Journal:  Indian J Radiol Imaging       Date:  2010-02

9.  Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta.

Authors:  J A Meganck; D L Begun; J D McElderry; A Swick; K M Kozloff; S A Goldstein; M D Morris; J C Marini; M S Caird
Journal:  Bone       Date:  2013-06-14       Impact factor: 4.398

10.  Non-traumatic hypertrophic callus of the fibula mimicking osteosarcoma in osteogenesis imperfecta type V: a case report.

Authors:  Arnold Radu; Rene Epunza Kanza; Dezso Barabas; Michel Lessard; Michel Berube
Journal:  Skeletal Radiol       Date:  2014-04-15       Impact factor: 2.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.